論文・技術情報追加のお知らせ

1. Drug-induced vanishing bile duct syndrome: A real world pharmacovigilance study using the FDA adverse event reporting system.

薬剤性バニシング胆管症候群に関するFAERSを用いた安全性解析。

対象DB：FAERS

2. A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025.

カルバペネム系薬の血液毒性を解析。メロペネムで広範な毒性シグナル。

対象DB：FAERS

3. A real-world pharmacovigilance study of Cilostazol based on the FDA Adverse Event Reporting System:A Cross-Sectional Disproportionality Analysis.

シロスタゾールの安全性をFAERSに基づきリアルワールドで解析。

対象DB：FAERS

4. Drug-associated paronychia: Pharmacovigilance signals from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the Canada Vigilance Adverse Reaction Database (CVARD).

薬剤性爪囲炎のシグナルをFAERSで解析。EGFR阻害薬等の関連を調査。

対象DB：CVAR,FAERS

5. Prenatal exposure to antiseizure medications and risk of autism spectrum disorder in offspring: an integrated pharmacovigilance and two-sample mendelian randomization study.

妊娠中の抗てんかん薬曝露と自閉症スペクトラムリスクの関連を調査。

対象DB：EudraVigilance,FAERS

6. Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System.

CGRP拮抗薬（片頭痛薬）の心血管安全性シグナルをFAERSで特定。

対象DB：FAERS

7. Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).

チルゼパチドとセマグルチドの婦人科的安全性をFAERSで比較。

対象DB：FAERS

8. Diphtheria-tetanus-acellular pertussis vaccine safety in children under 7 years: a post-marketing analysis of the U.S. vaccine adverse event reporting system.

7歳未満のDTPワクチンの安全性をVAERSデータで評価。

対象DB：FAERS,VAERS

9. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal nanoparticle-formulated and conventional anticancer irinotecan.

FAERSを用い2種のイリノテカンを比較。通常型は下痢や血球減少に注意。

対象DB：FAERS

10. Unveiling the hidden risks of nanomedicine-based drug delivery: a comparative evaluation of drug safety profiles of liposomal irinotecan and conventional irinotecan.

ナノメディシン製剤の隠れたリスクを従来製剤と比較・評価。

対象DB：FAERS

11. Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System.

トリプルモノアミン再取り込み阻害薬の副作用プロファイルを解析。

対象DB：FAERS

12. Potential risk signals for drug-related osteomyelitis: a comprehensive disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database.

薬剤性骨髄炎の潜在的リスクシグナルを大規模データベースで解析。

対象DB：FAERS

13. Evaluation of bone safety and antiseizure medications: a multi-source pharmacovigilance and Mendelian randomization analysis.

抗てんかん薬と骨の安全性。複数DBを用いた統合解析。

対象DB：FAERS

14. Risk signals and clinical characteristics of serious adverse events of neutropenia associated with pembrolizumab: a FAERS database study.

抗がん剤等による重篤な好中球減少症のリスクシグナルを解析。

対象DB：FAERS

15. Analysis of drug-induced adverse reactions affecting appetite and taste using the Japanese Adverse Drug Event Report Database.

食欲や味覚に影響を与える薬剤性副作用をFAERSを用いて解析。

対象DB：JADER

16. Novel objective-subjective pain assessment score results in decreased opioid prescription after elective spine surgery: a prospective pilot study.

新しい疼痛評価スコアの導入によるオピオイド処方量の減少効果。

対象DB：JADER

17. Drug-induced male infertility: a real-world study using FAERS and EudraVigilance databases.

薬剤性男性不妊についてFAERSとEudraVigilanceを用い解析。

対象DB：EudraVigilance

18. Selective oestrogen receptor modulators and Alzheimer s disease: a real-world pharmacovigilance study.

SERM（選択的エストロゲン受容体調節薬）とアルツハイマー病リスク。

対象DB：VigiBase

19. Cardiac Valvular Incompetence Associated With Selective Serotonin Reuptake Inhibitors (SSRIs): A Disproportionality and Risk Factor Analysis From Global Safety Reports.

SSRI使用に関連する心臓弁膜症のリスクをFAERSデータで解析。

対象DB：VigiBase

20. Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases-An update.

副作用DBにおける間質性肺疾患のコーディング変更の影響を解析。

対象DB：VigiBase

21. Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review.

オクレリズマブ誘発性大腸炎について、VigiBaseと症例を解析。

対象DB：VigiBase

22. Hypertension increases risk of deep vein thrombosis after knee arthroplasty: A nationwide propensity score-matched study in Japan.

高血圧が膝関節置換術後の深部静脈血栓症リスクを高めることを解明。

対象DB：DPC

23. Cost Analysis of Abdominal Aortic Aneurysm Repair: The Economic Impact of Rising Surgical Material Costs on Public Health Insurance.

腹部大動脈瘤修復術のコスト解析。資材費上昇による経済的影響。

対象DB：DPC

24. Association between diabetes and in-hospital outcomes in patients with metabolic dysfunction-associated steatotic liver disease hospitalized for cardiovascular disease: A nationwide database study.

代謝障害関連脂肪性肝疾患（MASLD）患者の入院予後と糖尿病の関連。

対象DB：DPC

25. Nationwide trends in mediastinal tumor and myasthenia gravis surgery in Japan: a decade claims-based analysis (2014-2023).

日本における縦隔腫瘍および重症筋無力症手術の全国的な変遷を調査。

対象DB：NDB

26. Assessment of Predictive Factors That Shorten Duration of Treatment in Patients With Multiple Myeloma Using AI: Real-World Longitudinal Study Using Data From Medical Data Vision Claims Database.

機械学習で国内骨髄腫の治療期間短縮要因を解析。

対象DB：MDV

27. Persistence and Long-Term Disease Control of Interleukin-17 Inhibitors and Interleukin-23 Inhibitors in Patients with Psoriasis: A Nationwide Cohort Study in Japan.

乾癬に対するIL-17およびIL-23阻害薬の長期治療継続率を比較。

対象DB：MDV

28. Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.

知的障害を持つ男性の前立腺がんケアに関する住民ベースの研究。

対象DB：CPRD

29. Initial Treatment of COPD with LABA-LAMA Versus LAMA: Real-World Comparative Effectiveness and Safety.

COPD初期治療におけるLAMA単剤に対するLABA-LAMAの有効性比較。

対象DB：CPRD

30. Twenty-year trends in ethnicity with type 2 diabetes across age at diagnosis: observational study in 11 million individuals in England.

診断時年齢別の2型糖尿病の民族的傾向に関する20年間の調査。

対象DB：CPRD

31. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.

GLP-1受容体作動薬と非動脈炎性前部虚血性視神経症リスクを解析。

対象DB：CPRD

32. Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing UK Population with Subclinical Hypothyroidism: Emulated Target Trial (ACEL-UK-ETT).

英国の高齢者におけるレボチロキシン使用の心血管への影響を評価。

対象DB：THIN

33. Efficacy and safety of FHR-SM, a combined extract of Siegesbeckia glabrescens Makino and Mori ramulus, for alleviating alcohol-induced hangover symptoms.

変形性膝関節症に対するFHR-SM抽出物の有効性と安全性（RCT）。

対象DB：KAERS

34. Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge.

アトルバスタチン誘発肝障害後のスタチン再投与の転帰を解析。

対象DB：FPVD

35. Impact of Impaired Fasting or Diabetes Compared with That of Smoking Habit on Tooth Loss.

高血糖および喫煙が歯の喪失リスクに与える影響を国内データで解析。

対象DB：DeSC